Jump to content

Harrison Stafford

Legacy Members
  • Posts

    2912
  • Joined

  • Last visited

Everything posted by Harrison Stafford

  1. Biotech is a bitch.
  2. Patrick Soon-Shiong, Executive Chairman of IBRX, is providing non-convertible debt financing of $30 million while the company sorts this out. It doesn’t sound like we have incoming dilution.
  3. The FDA fucked us
  4. UUUU waking up +.48 to 6.53. Holding 20,000 shares UUUU cost basis 6.19. RVPH 3000 shares GTC order filled at 8.05. Have another GTC order for 3000 more shares at 7.60. Holding 6000 shares of RVPH.
  5. As I posted earlier, I bought IBRX with the expectation of holding it until it reaches three digits or zero and that plan hasn’t changed. The ride ain’t over. Keep the faith
  6. IBRX finishes the day + .87 to 6.41 with 5x the normal volume. IBRX is up over 100% in the last 5 days. We’re bloodied, but not beaten.
  7. Hoping for a partnership with big pharma following FDA approval.
  8. FDA approval should send the stock into the teens. If IBRX announces a good partnership deal with big pharma, it could add to that, but it really depends on the nature of the agreement...ie partnering and distributing vs buying rights to distribute. The more cash it gives IBRX, the better. Then, there are all those other late stage drug trials in the pipeline. And none of this takes into account the possibility that money flow maybe, possibly, finally returns to the bludgeoned biotech sector. When buying stock in IBRX the plan was to ride it to three digits or ride it to 0 and that plan hasn’t changed. IBRX isn’t simply a stonk. It’s a biotech stonk. The risk is sky high and the volatility is madness. Holding 27,800 shares of IBRX at a cost basis of 9.77. Buckle up ‘cause the ride with IBRX ain’t over
  9. I love the smell of a short squeeze in the morning
  10. Now, IBRX +2.13 to 6. I love the smell of a short squeeze in the morning
  11. IBRX +1.34 to 5.21. How are those options looking?
  12. IBRX +.64 to 4.51. The biotech sector continues its ascent.
  13. Let’s be clear. We’re all simpletons playing in the stonk world.
  14. Sold 10,000 shares of UUUU and 12,900 shares of EOSE to raise cash to buy more RVPH. Set a GTC order to buy 3000 shares of RVPH at 8.05 and another 3000 shares at 7.60. That still leaves me with plenty of dry powder to buy more should there be a mega down day. There’s always a risk, but if their drug hits it’s endpoints in July, we’re talking mucho dinero. Holding 3000 shares of RVPH at 4.89.
  15. Somebody thinks IBRX’s bladder cancer drug is going to get FDA approval. Let those options ride
  16. IBRX +.54 to 3.90. Yowza.
  17. RVPH +.90 to 8.70. Hit a 52 wk high today at 9.25. RVPH, I surrender.
  18. Sold 25,000 shares of AMYZF to raise capital to buy more RVPH. The first level to watch is 7-7.25. Still have 125,000 shares of AMYZF. Stonk life, baby
  19. RVPH +1.00 to $8.11. Damn. Recalibrating entry point to add to that position. IBRX +.20 to $3.28 and GERN +.13 to $2.61. Biotechs on the move.
  20. There’s a new position we haven’t tried. Field position
  21. I think there’s still time between now and July or so when their current trial ends. Unless somebody announces a partnership or a buyout.(less likely), there should be some pull backs in the stock. Still hoping for sub $6.
  22. With a down day in the market, IBRX closes flat and stays north of $3/share. Hubba, hubba.
  23. IBRX rises from the dead. Waiting (and hoping) for RVPH to dip below $6 to buy more shares.
  24. Not the best of choices with the nickname
×
×
  • Create New...